⌘+K

Pulse Explore Communities Researchers Journals

Browser extensionInstagram

Home Communities Explore

August 30, 2024Inflammatory Bowel Diseases

Real-World Comparison of Effectiveness, Treatment Persistence, and Safety of First-Line Advanced Therapies at 1 Year for Ulcerative Proctitis

Rahul S. Dalal Lindsay Clarke Alex Carlin Heidy Cabral Jessica R. Allegretti

View at Publisher

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

In this retrospective cohort study, vedolizumab was associated with higher odds of steroid-free clinical remission at 1 year compared to anti-TNF agents for bio-naïve patients with ulcerative proctitis.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Dalal et al. (2024) studied this question.

synapsesocial.com/papers/68e5a3eab6db64358753da4a https://doi.org/10.1093/ibd/izae215

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Long-Term Comparative Outcomes of TNF-α Antagonists vs. Vedolizumab as First-Line Biologic Therapy for Refractory Ulcerative Proctitis: A Propensity-Matched StudyCohort Study · 2026 · 1 citations
2A Real-World Observational Study of Second-Line Anti-TNFα Treatment in Patients with Ulcerative Colitis who Received Vedolizumab as a First-Line BiologicCohort Study · 2026
3Long-term efficacy and safety of vedolizumab compared with infliximab in biologic-naive ulcerative colitis: a systematic review and meta-analysisMeta-Analysis · 2026
4Vedolizumab vs TNF Antagonists and Long-Term Outcomes in Ulcerative ColitisCohort Study · 2026
5Real-life treatment persistence and treatment outcomes of Finnish patients with inflammatory bowel disease receiving vedolizumab as first-line biological treatment2024 · 2 citations
6Real-World Effectiveness and Safety of Vedolizumab and Ustekinumab in Biologic-Naive Patients With Crohn’s DiseaseHuman Clinical Trial · 2026 · 1 citations
7Real‐World Comparison of Vedolizumab and Ustekinumab in TNF Inhibitor–Experienced Ulcerative Colitis Patients Followed by Therapeutic Drug MonitoringOriginal Research · 2026
8Long-term clinical and endoscopic efficacy of vedolizumab and therapeutic persistence in patients with ulcerative colitis in China: a multicenter observational studyObservational Study · 2026
9Trends in common laboratory markers during pregnancy in women with IBD in clinical remissionInflammatory Bowel Diseases · 2026
10Effects of upadacitinib on lipid profiles and their relationship with inflammation in patients with inflammatory bowel disease: a real-world longitudinal cohort studyInflammatory Bowel Diseases · 2026

More from Inflammatory Bowel Diseases

More from Harvard University

More from Brigham and Women's Hospital